Zidovudine (AZT)• Approved by FDA and HPB for use in pregnancy• FDA pregnancy
category C• No documented toxic effects in humans, aside from reversible anemia in …

Objective The package of care to reduce HIV mother to child transmission (MTCT) has
evolved significantly since trials of ante and intrapartum antiretroviral therapy (ART) in 1994 …

Zidovudine therapy seems to be effective for reducing vertical transmission of HIV infection
and preventing paediatric AIDS. Besides those cases in which it is indicated, zidovudine …

In the current issue of HIV Medicine, Read et al.[1] report on the experience with zidovudine
monotherapy (ZDVm) in pregnancy in the period 2001–2005. Among 80 women treated with …

The recently published Protocol 076 study (ACTG 076/ANRS 024) showed that zidovudine
significantly decreased the relative risk of maternal HIV transmission by 71.5% compared …

The aim of antiretroviral therapy in pregnancy is to deliver a healthy uninfected child to a
healthy mother, without prejudicing the future treatment opportunities of the mother. The use …

Increasing rates of HIV infection in women worldwide, especially among those of
childbearing age, reinforce the importance of understanding the management of HIV in …

These recommendations update the February 4, 2002, guidelines developed by the Public
Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human …

The incidence and prevalence of human immunodeficiency virus (HIV) infection in women of
child-bearing age continue to increase both internationally and in Canada. The care of HIV …

Background and Methods Maternal-infant transmission is the primary means by which
young children become infected with human immunodeficiency virus type 1 (HIV). We …